ROTTERDAM, Netherlands and SAN DIEGO, Oct. 8, 2024
/PRNewswire/ -- SkylineDx, an innovative diagnostics company
specializing in the research and development of molecular
diagnostics for oncology, inflammatory, and infectious diseases,
announces that late-breaking data evaluating its Merlin test will
be presented as part of the Plenary Session and a poster
presentation at the upcoming Society for Melanoma Research (SMR)
being held from October 10-13, 2024,
in New Orleans, LA.
|
The oral
presentation will be part of Plenary Session 10: Late Breaking
Clinical Abstracts
|
|
Oral
|
"Prospective
Multicenter Evaluation (MERLIN_001 Trial) of Clinicopathologic and
Gene
|
|
Expression Profile Test
to Predict Sentinel Node Status in T1-T3 cNO Melanoma
|
|
Date
|
Sunday, October
13
|
|
Time
|
10:45 AM
CDT
|
|
Presenter
|
Vernon K. Sondak, MD,
Department Chair, Cutaneous Oncology, Moffitt Cancer
Center
|
|
|
|
Poster Presentation
Details
|
|
Poster
|
CP-GEP Identifies T1a
Melanoma Patients at Risk of Sentinel Lymph Node
Metastasis
|
|
Date
|
Friday, October
11
|
|
Time
|
1:00 – 2:00 PM
CDT
|
|
Presenter
|
Alex Meves, MD, MBA,
Dermatologist, Mayo Clinic
|
About CP-GEP (Merlin test)
CP-GEP is a non-invasive prediction model for cutaneous melanoma
patients that combines clinicopathologic (CP) variables with gene
expression profiling (GEP). This model is able to identify
cutaneous melanoma patients at low-risk for nodal metastasis who
may forgo the sentinel lymph node biopsy (SLNB) procedure. The
CP-GEP model was developed by Mayo Clinic and SkylineDx BV and it
has been clinically validated in multiple studies. More information
(including references) may be obtained at www.falconprogram.com and
merlinmelanomatest.com. The test has been launched in the United States and Europe as Merlin test. SkylineDx collaborates
with diagnostic service providers globally to bring this test to
market and increase patient access. In the United States, Tempus is commercializing
Tempus Merlin test. Quest Diagnostics launched their own LDT
version of the CP-GEP model in the United
States under the brand name MelaNodal Predict™.
About SkylineDx
SkylineDx is a biotechnology company focused on research &
development of molecular diagnostics in oncology inflammatory, and
infectious diseases. SkylineDx uses its expertise to bridge the gap
between academically discovered gene expression signatures and
commercially available diagnostic products with high clinical
utility, assisting healthcare professionals in accurately
determining the type or status of disease or predicting a patient's
response to treatment. Based on test results, healthcare
professionals can tailor the treatment approach to the individual
patient. SkylineDx is headquartered in Rotterdam. the Netherlands, complemented by a
U.S. base of operations and a CAP/CLIA certified laboratory in
San Diego California, USA. To
learn more about SkylineDx, please visit www.skylinedx.com.
View original
content:https://www.prnewswire.co.uk/news-releases/skylinedx-announces-upcoming-oral-presentation-at-the-21st-international-congress-of-the-society-for-melanoma-research-302270185.html